The global proteomics market is entering a period of accelerated expansion as life sciences and healthcare industries increasingly prioritize protein-level analysis to understand disease mechanisms and therapeutic response. According to industry projections, the proteomics market is expected to grow from US$ 34.56 billion in 2024 to US$ 85.91 billion by 2031, registering a strong compound annual growth rate (CAGR) of 11.9% during the forecast period from 2025 to 2031.

Proteomics—the large-scale study of proteins, their structures, functions, and interactions—has emerged as a critical complement to genomics. While genetic information outlines biological potential, proteins represent real-time biological activity, offering direct insight into disease progression and treatment efficacy. This functional relevance has positioned proteomics as a foundational technology for precision medicine, targeted therapeutics, and advanced diagnostics.

Market Growth Drivers

Several factors are contributing to the rapid expansion of the proteomics market. Rising prevalence of chronic and complex diseases such as cancer, cardiovascular disorders, and neurological conditions has increased demand for more accurate diagnostic tools. Proteomics enables the identification of disease-specific protein biomarkers, improving early diagnosis and patient stratification.

Additionally, pharmaceutical and biotechnology companies are increasingly adopting proteomics to improve drug discovery efficiency. By enabling target identification, validation, and mechanism-of-action studies, proteomics helps reduce high attrition rates and late-stage clinical failures.

Technological advancements in analytical instrumentation, coupled with improvements in bioinformatics and automation, have also lowered barriers to adoption, enabling broader use across research institutions, hospitals, and commercial laboratories.

Product and Service Segmentation

The proteomics market is segmented by product and service into instrumentation technologies, reagents and consumables, and software and services.

Instrumentation technologies account for a significant share of market revenue. Advanced mass spectrometry systems, chromatography platforms, and emerging protein sequencing technologies are essential for accurate protein identification and quantification. Companies such as SCIEX and Biognosys are widely recognized for driving innovation in high-resolution proteomic instrumentation, while QUANTUM-SI INCORPORATED is gaining attention for its next-generation semiconductor-based protein sequencing solutions.

Reagents and consumables represent a recurring revenue segment, supporting essential workflow steps such as sample preparation, labeling, separation, and detection. Consistent demand from pharmaceutical companies and research laboratories ensures long-term stability for this segment.

Software and services are gaining strategic importance as proteomics datasets grow in volume and complexity. Advanced data analysis platforms enable interpretation of large-scale protein data, while specialized service providers such as Creative Proteomics, Promise Proteomics, and Shantani offer outsourced analytical expertise to organizations lacking in-house infrastructure.

Applications and End Users

By application, the market is primarily driven by drug discovery and development and clinical diagnostics. Drug discovery remains a dominant application, as proteomics enhances understanding of disease biology and therapeutic targets. Clinical diagnostics is emerging as a high-growth segment, supported by increasing adoption of protein-based biomarker tests in hospital settings.

In terms of end users, pharmaceutical and biotechnology companies represent the largest segment, followed by research and clinical laboratories. Hospitals are increasingly integrating proteomics into translational research and personalized medicine initiatives.

Competitive Landscape

The global proteomics market is highly competitive, with key players including Proteome Sciences, Biognosys, Creative Proteomics, Shantani, Olink, SomaLogic Operating Co., Inc., QUANTUM-SI INCORPORATED, Proteomics International, Promise Proteomics, and SCIEX. These companies continue to invest in innovation, partnerships, and geographic expansion to strengthen their market positions.

Related Reports

• ·         Mass Spectrometry Market Outlook, Segments, Recent Developments, and Insights by 2031
• ·         Mass Spectrometry Software Market Key Players and Forecast by 2027
• ·         Recombinant Proteins Market Dynamics and Developments by 2031

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:

Contact Person: Ankit Mathur

E-mail: ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in: 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch